Switch theme
Sign up to access all valuation multiples
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
1945
25K+
LTM Revenue $10.6B
LTM EBITDA $2.8B
$45.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alcon has a last 12-month revenue (LTM) of $10.6B and a last 12-month EBITDA of $2.8B.
In the most recent fiscal year, Alcon achieved revenue of $11.9B and an EBITDA of $3.2B.
Alcon expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alcon valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.6B | XXX | $11.9B | XXX | XXX | XXX |
| Gross Profit | $6.3B | XXX | $6.6B | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | $2.8B | XXX | $3.2B | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $2.2B | XXX | $1.7B | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $1.6B | XXX | $1.2B | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.6B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alcon's stock price is CHF 71 (or $85).
Alcon has current market cap of CHF 35.0B (or $42.0B), and EV of CHF 38.1B (or $45.8B).
See Alcon trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $45.8B | $42.0B | XXX | XXX | XXX | XXX | $3.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alcon has market cap of $42.0B and EV of $45.8B.
Alcon's trades at 3.8x EV/Revenue multiple, and 14.2x EV/EBITDA.
Equity research analysts estimate Alcon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alcon has a P/E ratio of 26.2x.
See valuation multiples for Alcon and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $42.0B | XXX | $42.0B | XXX | XXX | XXX |
| EV (current) | $45.8B | XXX | $45.8B | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | 16.5x | XXX | 14.2x | XXX | XXX | XXX |
| EV/EBIT | 21.0x | XXX | 27.0x | XXX | XXX | XXX |
| EV/Gross Profit | 7.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 26.2x | XXX | 34.4x | XXX | XXX | XXX |
| EV/FCF | 30.5x | XXX | 27.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlcon's last 12 month revenue growth is 3%
Alcon's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Alcon's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alcon's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alcon and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | -2% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | 27% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alcon acquired XXX companies to date.
Last acquisition by Alcon was XXXXXXXX, XXXXX XXXXX XXXXXX . Alcon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alcon founded? | Alcon was founded in 1945. |
| Where is Alcon headquartered? | Alcon is headquartered in Switzerland. |
| How many employees does Alcon have? | As of today, Alcon has 25K+ employees. |
| Who is the CEO of Alcon? | Alcon's CEO is Mr. David J. Endicott. |
| Is Alcon publicy listed? | Yes, Alcon is a public company listed on SWX. |
| What is the stock symbol of Alcon? | Alcon trades under ALC ticker. |
| When did Alcon go public? | Alcon went public in 2019. |
| Who are competitors of Alcon? | Similar companies to Alcon include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Alcon? | Alcon's current market cap is $42.0B |
| What is the current revenue of Alcon? | Alcon's last 12 months revenue is $10.6B. |
| What is the current revenue growth of Alcon? | Alcon revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Alcon? | Current revenue multiple of Alcon is 4.3x. |
| Is Alcon profitable? | Yes, Alcon is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alcon? | Alcon's last 12 months EBITDA is $2.8B. |
| What is Alcon's EBITDA margin? | Alcon's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Alcon? | Current EBITDA multiple of Alcon is 16.5x. |
| What is the current FCF of Alcon? | Alcon's last 12 months FCF is $1.5B. |
| What is Alcon's FCF margin? | Alcon's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Alcon? | Current FCF multiple of Alcon is 30.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
